Modern biomarkers of acute kidney injury
The results of published studies of modern biomarkers used in the diagnosis of acute kidney injury (AKI) were summarized. The search was carried out in the PubMed/MEDLINE, Scopus, eLibrary databases. AKI occurs in 10–15% of all inpatients and 50% of intensive care patients, and affects economic aspe...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2023-04-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/799 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394937728073728 |
|---|---|
| author | D. I. Korabelnikov M. O. Magomedaliev |
| author_facet | D. I. Korabelnikov M. O. Magomedaliev |
| author_sort | D. I. Korabelnikov |
| collection | DOAJ |
| description | The results of published studies of modern biomarkers used in the diagnosis of acute kidney injury (AKI) were summarized. The search was carried out in the PubMed/MEDLINE, Scopus, eLibrary databases. AKI occurs in 10–15% of all inpatients and 50% of intensive care patients, and affects economic aspects of treatment and rehabilitation. The literature review allowed to draw conclusions about the significant advantage of new AKI biomarkers (cystatin C, neutrophil gelatinase-associated lipocalin, β2-microglobulin, kidney injury molecule-1, fatty acid binding protein) over the conventional glomerular filtration rate, serum creatinine and urinary volume. Serum creatinine increases only in cases when 50–60% of nephrons are damaged, urinary volume has limitations such as the overdiagnosis of AKI in dehydrated patients, the inability to assess based on a single measurement, and the need for regular and frequent follow-up. Modern biomarkers make it possible to verify renal dysfunction in advance, at the subclinical level. This allows to make a correction in the therapy of the underlying disease and initiate nephroprotection to prevent the development of AKI and the further development of multiple organ failure, which may be more effective than the treatment of already developed AKI. |
| format | Article |
| id | doaj-art-7ac7c0a61192434b8e48a1a4793a33de |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2023-04-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-7ac7c0a61192434b8e48a1a4793a33de2025-08-20T03:39:49ZrusIRBIS LLCФармакоэкономика2070-49092070-49332023-04-0116110.17749/2070-4909/farmakoekonomika.2023.171426Modern biomarkers of acute kidney injuryD. I. Korabelnikov0M. O. Magomedaliev1Moscow Haass Medical Social InstituteMoscow Haass Medical Social Institute; 1586 Military Clinical HospitaThe results of published studies of modern biomarkers used in the diagnosis of acute kidney injury (AKI) were summarized. The search was carried out in the PubMed/MEDLINE, Scopus, eLibrary databases. AKI occurs in 10–15% of all inpatients and 50% of intensive care patients, and affects economic aspects of treatment and rehabilitation. The literature review allowed to draw conclusions about the significant advantage of new AKI biomarkers (cystatin C, neutrophil gelatinase-associated lipocalin, β2-microglobulin, kidney injury molecule-1, fatty acid binding protein) over the conventional glomerular filtration rate, serum creatinine and urinary volume. Serum creatinine increases only in cases when 50–60% of nephrons are damaged, urinary volume has limitations such as the overdiagnosis of AKI in dehydrated patients, the inability to assess based on a single measurement, and the need for regular and frequent follow-up. Modern biomarkers make it possible to verify renal dysfunction in advance, at the subclinical level. This allows to make a correction in the therapy of the underlying disease and initiate nephroprotection to prevent the development of AKI and the further development of multiple organ failure, which may be more effective than the treatment of already developed AKI.https://www.pharmacoeconomics.ru/jour/article/view/799acute kidney injuryakibiomarkerscystatin cneutrophil gelatinase-associated lipocalinngalkidney injury molecule 1kim-1β2-microglobulinliver-type fatty acid binding proteinl-fabp |
| spellingShingle | D. I. Korabelnikov M. O. Magomedaliev Modern biomarkers of acute kidney injury Фармакоэкономика acute kidney injury aki biomarkers cystatin c neutrophil gelatinase-associated lipocalin ngal kidney injury molecule 1 kim-1 β2-microglobulin liver-type fatty acid binding protein l-fabp |
| title | Modern biomarkers of acute kidney injury |
| title_full | Modern biomarkers of acute kidney injury |
| title_fullStr | Modern biomarkers of acute kidney injury |
| title_full_unstemmed | Modern biomarkers of acute kidney injury |
| title_short | Modern biomarkers of acute kidney injury |
| title_sort | modern biomarkers of acute kidney injury |
| topic | acute kidney injury aki biomarkers cystatin c neutrophil gelatinase-associated lipocalin ngal kidney injury molecule 1 kim-1 β2-microglobulin liver-type fatty acid binding protein l-fabp |
| url | https://www.pharmacoeconomics.ru/jour/article/view/799 |
| work_keys_str_mv | AT dikorabelnikov modernbiomarkersofacutekidneyinjury AT momagomedaliev modernbiomarkersofacutekidneyinjury |